AXUMIN

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Japan, Lithuania, Poland, United States

Active ingredients

The drug AXUMIN contains one active pharmaceutical ingredient (API):

1 Fluciclovine ¹⁸F UNII 38R1Q0L1ZE - FLUCICLOVINE F-18

Fluciclovine ¹⁸F is a synthetic amino acid which is transported across mammalian cell membranes by amino acid transporters such as LAT-1 and ASCT2. The activities of LAT-1 and ASCT2 are known to be upregulated in prostate cancer, providing a mechanism for the enhanced accumulation of fluciclovine ¹⁸F in prostate cancer. Fluciclovine ¹⁸F is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer. Read about Fluciclovine ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AXUMIN Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09IX12		V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IX Other diagnostic radiopharmaceuticals for tumour detection
Discover more medicines within V09IX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1746514, 1746525
Country: FR	Base de données publique des médicaments	Identifier(s): 67044107, 69890458
Country: JP	医薬品医療機器総合機構	Identifier(s): 43004A5A1022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1082981, 1082982, 1086756, 1086757
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100391813, 100417079
Country: US	FDA, National Drug Code	Identifier(s): 69932-001